Pipeline Faceoff

Data updated: May 26, 2026

Compare clinical trial portfolios and competitive positioning

Quick compare:

Company A

Company B

🔒

Free preview: Pfizer vs Eli Lilly

See how this comparison works. Upgrade to Pro to compare any of 100 pharma companies side by side.

Unlock all comparisons →

Export to PDF

Select sections to include:

Company SummaryKey Insights

Today's Business

Current Portfolio (Revenue)Patent Cliff Risk

Future Pipeline

Head-to-Head ScorecardPipeline DepthPipeline Value

Competitive Landscape

Competitive Overlap MatrixCompetitive Intelligence

Key Insights

Future Pipeline

Head-to-Head Scorecard

Counts which company leads on each of 6 raw pipeline metrics — total trials, Phase 1–4, therapeutic areas. More wins = larger scale, not necessarily better outcomes.

Pipeline Depth

Pipeline comparison by phase

Success rates:P1:%P2:%P3:%

Pro Comparison: Verdict, Revenue, Patents, Competitive

See the AI analyst verdict, current revenue split, biologic + small-molecule patent cliffs, pipeline NPV, and indication-level competitive overlap.

Limited-time launch pricing

$99/month · $990/year

Save $198 - 2 months free - with yearly

Upgrade to Pro

Or explore free dashboards — PDUFA calendar, Trials Explorer, Biotechs, and more.

Analyst VerdictAI-enhanced

Today's Business

Current Portfolio

Top drugs by quarterly revenue

Patent Cliff Risk

Upcoming patent expirations — small molecules (Orange Book) + biologics (Purple Book + curated overrides)

Pipeline Value

Estimated worth accounting for clinical trial failure risk

Competitive Landscape

Competitive Overlap Matrix

Competitive Intelligence

Indication-level battleground analysis

Select two companies above to compare their portfolios